September 2018

New Product - Erlyand

Apalutamide (Erlyand) is an androgen receptor (AR) inhibitor that binds directly to the ligand binding domain of the AR. Apalutamide prevents AR nuclear translocation, inhibits DNA binding, impedes AR mediated transcription, and lacks androgen receptor agonist activity in preclinical studies. Erlyand is indicated for the treatment of non-metastatic, castration resistant prostate cancer. Patients should concurrently receive a gonadotropin-releasing hormone (GnRH) analogue, unless they have had a bilateral orchiectomy. Erlyand is contraindicated in women who are or may become pregnant. Erlyand tablets contain apalutamide 60 mg and are available in packs of 120.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia┬áPty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au